Wall Street brokerages expect that AbbVie Inc. (NYSE:ABBV) will post $6.97 billion in sales for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for AbbVie’s earnings. The highest sales estimate is $7.08 billion and the lowest is $6.85 billion. AbbVie posted sales of $6.43 billion during the same quarter last year, which would indicate a positive year over year growth rate of 8.4%. The company is expected to announce its next earnings results on Friday, October 27th.

On average, analysts expect that AbbVie will report full year sales of $6.97 billion for the current financial year, with estimates ranging from $27.68 billion to $27.98 billion. For the next year, analysts anticipate that the business will report sales of $30.68 billion per share, with estimates ranging from $30.03 billion to $32.15 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover AbbVie.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 154.76% and a net margin of 24.77%. The company had revenue of $6.94 billion for the quarter, compared to the consensus estimate of $6.93 billion. During the same quarter last year, the company posted $1.26 earnings per share. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year.

Several research analysts have weighed in on the company. BMO Capital Markets reaffirmed a “hold” rating and set a $63.00 price target on shares of AbbVie in a research report on Tuesday, April 18th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $85.00 price target on shares of AbbVie in a research report on Thursday, August 3rd. Vetr lowered AbbVie from a “buy” rating to a “hold” rating and set a $72.72 price target on the stock. in a research report on Wednesday, June 14th. Leerink Swann reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, June 22nd. Finally, BidaskClub lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $75.35.

In other AbbVie news, Chairman Richard A. Gonzalez sold 87,899 shares of the company’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $71.02, for a total value of $6,242,586.98. Following the transaction, the chairman now directly owns 342,353 shares of the company’s stock, valued at approximately $24,313,910.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Richard A. Gonzalez sold 65,861 shares of the company’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $71.00, for a total value of $4,676,131.00. Following the completion of the transaction, the chief executive officer now directly owns 342,353 shares in the company, valued at $24,307,063. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 600,026 shares of company stock worth $41,852,724. Insiders own 0.23% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Lebenthal Asset Management LLC raised its position in shares of AbbVie by 0.7% in the fourth quarter. Lebenthal Asset Management LLC now owns 149,940 shares of the company’s stock worth $9,389,000 after buying an additional 1,026 shares in the last quarter. RB Capital Management LLC purchased a new position in shares of AbbVie during the fourth quarter worth approximately $299,000. Pinnacle Financial Partners Inc. raised its position in shares of AbbVie by 4.3% in the fourth quarter. Pinnacle Financial Partners Inc. now owns 75,426 shares of the company’s stock worth $4,723,000 after buying an additional 3,123 shares in the last quarter. First Light Asset Management LLC purchased a new position in shares of AbbVie during the fourth quarter worth approximately $260,000. Finally, Bridgeworth LLC purchased a new position in shares of AbbVie during the fourth quarter worth approximately $368,000. 67.89% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AbbVie (ABBV) traded up 0.35% during trading on Friday, reaching $71.47. The company’s stock had a trading volume of 4,398,003 shares. The stock’s 50 day moving average price is $72.12 and its 200 day moving average price is $66.41. The company has a market cap of $113.75 billion, a PE ratio of 17.58 and a beta of 1.50. AbbVie has a 52 week low of $55.06 and a 52 week high of $75.04. AbbVie also was the recipient of unusually large options trading on Monday. Traders acquired 278 put options on the stock. This is an increase of approximately 121% compared to the average volume of 126 put options.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date of this dividend is Wednesday, July 12th. AbbVie’s dividend payout ratio is 62.90%.

COPYRIGHT VIOLATION WARNING: “$6.97 Billion in Sales Expected for AbbVie Inc. (NYSE:ABBV) This Quarter” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/19/6-97-billion-in-sales-expected-for-abbvie-inc-nyseabbv-this-quarter-updated.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Get a free copy of the Zacks research report on AbbVie (ABBV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.